Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 771-777

  Tsunoda, Yuko ^a   Suzuki, Kenya ^a   Tsunoda, Akira ^a   Takimoto, Masafumi ^a   Kusano, Mitsuo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil related genes; Breast cancer; Oral fluorouracil derivatives; Prognosis

Indexed keywords

AROMATASE INHIBITOR; DEHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXIDOREDUCTASE; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 77349107863     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000697     Document Type: Article

References (25)

1. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E III, Schilsky RL, Wood WC, Muss HB and Norton L: Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983, 2003.
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martio S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB and Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer. First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439, 2003.
3. Kasumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugimachi K, Nakazato H and Abe O: Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64: 146-153, 2003.
4. Fumoleau P, Larqillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z and Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastati breast cancer. Eur J Cancer 40: 536-542, 2004.
5. Taira N, Aogi K, Ohsumi S, Takashima S, Nishimura R, Doihara H and Saeki T: S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. Breast Cancer 13: 220-204, 2006.
6. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K and Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur pulas uracil, or both in women with nodenegative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005.
7. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Nanashima A, Yamaguchi H, Yasutake T, Nagayasu T and Tagawa Y: Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. Cancer Lett 204: 97-104, 2004.
8. Ichikawa W: Prediction of clinical outcome of fluoropyrimidinebased chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 9: 145-155, 2006.
9. Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M: Evaluation of biomarkers associated with 5-FU sensitivity for non-smallcell lung cancer patients postoperatively treated with UFT. Br J Cancer 95: 607-615, 2006.
10. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johnsson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI and Denenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, carcinoma sequence. J Gastrointes Surg 4: 135-142, 2000.
11. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
12. Gibson UE, Heid CA and Williams PM: A novel method for real-time quantative RT-PCR. Genome Res 6: 995-1011, 1996.
13. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aheme GW, Hardcastle A, McCarthy K and Jackman AL: Thymidykate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9: 792-801, 2003.
14. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA and Liotta LA: Laser capture microdossection. Science 274: 998-1001, 1996.
15. Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112: 967-973, 2004.
16. Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y and Morishita Y: Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86: 222-225, 2002.
17. Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV and Sugihara K: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 223: 103-111, 2005.
18. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for opotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
19. Hakamada Y, Tsuchida A, Arima M, Kubouchi T, Tokita H, Ota D, Kaise H, Aoki T, Kusama M and Aoki T: Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy. Int J Mol Med 16: 309-314, 2005.
20. Barankiewicz J and Henderson JF: Ribose 1-phosphate metabolism in Ehrlich ascites tumor cells in vitro. Biochim Biophys Acta 479: 371-377, 1977.
21. Toi M, Atiqur RM, Bando H and Chow LW: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 158-166, 2005.
22. Reif M, Lejeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bcknell R and Harris AL: Expression of the angiogenic factors vascular endothelial-cell browth-factor, acidic and basic fibroblast growth-factor, tumorgrowth factor-β-1, platelet-derived endothelial-cell growthfactor, placenta growth-factor, and pleiotrophin in human primary breast-cancer and its relation to angiogenesis. Cancer Res 57: 963-969, 1997.
23. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC and Harris AL: Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumorinfiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62: 1326-1329, 2002.
24. Brown NS, Jones A, Fujiyama C, Harris AL and Bicknell R: Thymidine phosphorylase induces carcinoma cell oxidative stress and promoters secretion of angiogenic factors. Cancer Res 60: 6298-6302, 2000.
25. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and lowdose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346, 2003.